FDA Accepts Supplement Application for Artesunate by Amivas
The FDA has accepted a supplemental application for Artesunate (NDA213036) submitted by Amivas.
Therapeutic Area
Therapeutic area intelligence for Antimalarial with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.